24% of patients will wait 5 months or more to get a myeloma diagnosis

MPE, MyelomaLeave a comment

Today is European Myeloma Day, a date to raise awareness about the most important issues for European myeloma patients. The findings of a recent report developed by Myeloma Patients Europe (MPE) are the driving reason for early diagnosis to be the focus of European Myeloma Day this year. By raising awareness of myeloma and disseminating an important tool called Myeloma Diagnosis Pathway, the myeloma patient community aims to improve early diagnosis and therefore patients’ lives.…

MPE attending International Myeloma Society (IMS) Annual Meeting in Athens

MPE, NewsLeave a comment

Myeloma Patients Europe (MPE) is attending the International Myeloma Society (IMS) Annual Meeting in Athens, Greece, from 27 – 30 September. This year, the IMS meeting corresponds with European Myeloma Day, allowing us to engage with the whole myeloma community to mark this important event.   The IMS Annual Meeting brings together myeloma experts from research, nursing, clinical and patient advocacy backgrounds to discuss the latest knowledge and developments in the field. It is a…

EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®

Access, Myeloma, NewsLeave a comment

On September 15, 2023, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has recommended non-renewal of marketing authorisation for belamaf mafadotin (Blenrep®).   Blenrep is currently approved for myeloma patients who have received at least four previous treatments and have stopped responding to at least one proteasome inhibitor (e.g., bortezomib), one immunomodulatory agent (e.g., lenalidomide), and an anti-CD38 monoclonal antibody (e.g., daratumumab), and whose cancer has worsened since…

EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisation

Access, Myeloma, NewsLeave a comment

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has granted a positive opinion on the application for an extended marketing authorisation (i.e. a license) for melphalan flufenamide (Pepaxti), also called melflufen.   Melflufen, in combination with dexamethasone,  is currently licenced in the EU for treating myeloma patients who have received at least three prior lines of therapy and are refractory to at least one proteasome inhibitor (such as…

Job Offer – Access and Policy Manager

MPELeave a comment

Job Title: Access and Policy Manager Position Type: Full time/permanent  Location: Home-based in Belgium, UK, Germany, France or Spain. Other locations in the EU would be considered depending on experience Travel required: 30 days / year (approx.) Gross salary range: 40.000 – 50.000 EUR/year (35.000-45.000 GBP/year)   If you wish to apply or have any questions, please send an email to  with a cover letter and CV.   As Access and Policy Project Manager, you will work…